z-logo
Premium
Decline in renal function following intestinal transplant: is the die cast at 3 months?
Author(s) -
Rutter Charlotte S.,
Russell Neil K.,
Sharkey Lisa M.,
Amin Irum,
Butler Andrew J.
Publication year - 2021
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.14249
Subject(s) - medicine , renal function , renal transplant , urology , tacrolimus , transplantation , kidney disease , incidence (geometry) , kidney , gastroenterology , surgery , physics , optics
This study reports the incidence of chronic kidney disease (CKD) after intestinal transplant (IT) at a single, adult center in the United Kingdom. Methods A retrospective review of IT was undertaken. Methods of renal function assessment pre‐transplant were compared. Post‐transplant renal function and renal sparing strategies were analyzed. Results There was a 30% variation ( p  < .001) in estimated glomerular filtration rate (eGFR) and normalized GFR at assessment. In the first 3 months post‐transplant, there was a 40% decline in eGFR which was irreversible. Liver inclusion was not protective with similar eGFR at 3 months (60 ml/min/1.73 m 2 ) compared with IT (55 ml/min/1.73 m 2 ). The rate of decline in the first 2 months was less in multivisceral transplant (MVT; 21%) than IT (52%) suggesting surgical magnitude did not contribute. Thirty percentage of recipients had acute cellular rejection post‐transplant; 58% of these were in the first 3 months with a higher proportion in MVT (64%) than IT (27%). Tacrolimus exposure did not correlate with decline in renal function over the first 3 months post‐transplant. Conclusion We demonstrated a 40% decline in renal function within 3 months post‐IT which was irreversible despite renal sparing strategies. Early intervention should be considered in patients with an acute decline in this post‐transplant period.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here